Develops drugs for rare genetic diseases.
Jun 2026Revenue $3.41B/yrExpenses $3.26B/yr
Reached break-even Mar 2022
Figures by year
When did Biomarin Pharmaceutical become profitable?
Its revenue passed its expenses in Mar 2022. In the 12 months to Jun 2026, revenue was $3.41B and expenses $3.26B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $3.22B | $2.81B | $409M |
| Dec 2024 | $2.85B | $2.37B | $484M |
| Dec 2023 | $2.42B | $2.23B | $186M |
| Dec 2022 | $2.10B | $1.94B | $161M |
| Dec 2021 | $1.85B | $1.93B | −$82.3M |
| Dec 2020 | $1.86B | $1.90B | −$43.4M |
| Dec 2019 | $1.70B | $1.80B | −$100M |
| Dec 2018 | $1.49B | $1.61B | −$124M |
| Dec 2017 | $1.31B | $1.33B | −$14.7M |
| Dec 2016 | $1.12B | $1.92B | −$803M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.